BioCryst Pharmaceuticals, Inc. Research and Development (R&D) Expenses Growth

Research and Development (R&D) Expenses Growth of BCRX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Research and Development (R&D) Expenses Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Research and Development (R&D) Expenses Growth for the quarter ending September 30, 2022 was 5.54% (a -67.87% decrease compared to previous quarter)
  • Year-over-year quarterly Research and Development (R&D) Expenses Growth decreased by -93.05%
  • Annual Research and Development (R&D) Expenses Growth for 2021 was 69.81% (a 370.1% increase from previous year)
  • Annual Research and Development (R&D) Expenses Growth for 2020 was 14.85% (a -43.17% decrease from previous year)
  • Annual Research and Development (R&D) Expenses Growth for 2019 was 26.13% (a -2.39% decrease from previous year)
  • Twelve month Research and Development (R&D) Expenses Growth ending September 30, 2022 was 34.87% (a -29.81% decrease compared to previous quarter)
  • Twelve month trailing Research and Development (R&D) Expenses Growth decreased by -50.05% year-over-year
Trailing Research and Development (R&D) Expenses Growth for the last four month:
30 Sep '22 30 Jun '22 31 Mar '22 31 Dec '21
34.87% 49.68% 70.98% 69.81%
Visit stockrow.com/BCRX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Research and Development (R&D) Expenses Growth of BioCryst Pharmaceuticals, Inc.

Most recent Research and Development (R&D) Expenses Growthof BCRX including historical data for past 10 years.

Interactive Chart of Research and Development (R&D) Expenses Growth of BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. Research and Development (R&D) Expenses Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 5.54% 17.24% 54.02%
2021 79.69% 65.22% 92.28% 42.08% 69.81%
2020 32.05% 20.4% -0.66% 8.63% 14.85%
2019 14.27% 14.15% 31.75% 49.09% 26.13%
2018 38.45% 25.68% 33.32% 9.96% 26.77%
2017 39.2% 24.13% 11.25% -18.51% 9.76%
2016 -36.17% -29.71% -14.27% 20.2% -16.15%
2015 2.9% 53.94% 49.31% 86.43% 40.47%
2014 19.68% 68.53% -3.99% 27.28% 23.49%
2013 76.03% -35.93% -9.78% -53.53% -14.68%
2012 -38.57% -20.06% -11.53% 15.83% -14.13%

Business Profile of BioCryst Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology